Lutetium Lu-177 vipivotide tetraxetan

Novartis secured public reimbursement of lutetium-177 vipivotide tetraxetan (Pluvicto) for PSMA-positive mCRPC patients in Canada. Pluvicto, approved by Health Canada in 2022 and the US FDA in 2022, offers hope for patients with advanced prostate cancer. The therapy still needs to be added to provincial formularies for patient access.

Nucs AI, using AI in precision medicine for prostate cancer, closed a $3.5M seed round to build its platform and seek FDA clearance. Their tools, DeepPSMA and SelectPSMA, enhance PSMA-PET/CT imaging and predict patient response to PSMA-targeted radiopharmaceuticals, aiming to improve prostate cancer care.

First study to report AEs associated with ¹⁷⁷Lu-PSMA-617 using FAERS database, identifying 6266 reports. Death (60.82%) most frequent severe outcome. Significant signals align with VISION trial, emphasizing hematological AEs. Renal toxicity not directly reflected. AEs prone to occur shortly after administration, with majority being grades 1–2. Study limitations include FAERS voluntary reporting and potential bias.

In metastatic hormone-sensitive prostate cancer (mHSPC), adding ¹⁷⁷Lu-PSMA-617 to androgen deprivation therapy (ADT) and chemotherapy doubled biochemical recurrence-free survival (BRFS) in the UpFrontPSMA trial. BRFS at 48 weeks increased from 16% to 41%. The median duration of freedom from castration resistance was 20 months with ¹⁷⁷Lu-PSMA-617 versus 16 months without it. Adverse events did not increase significantly with the three-drug combination.

MSK research identifies p53 gene mutation linked to breast cancer drug resistance, suggests CDK2/CDK4/6 inhibitor combo; phase 3 trial shows improved prostate cancer control with ¹⁷⁷Lu-PSMA-617; MSK-led study finds optimal radiation dose for spinal metastasis to prevent complications; proton therapy proves effective against recurrent head and neck cancers.

A novel epigenetic liquid biopsy platform could replace PSMA PET scans for detecting tumor PSMA expression in prostate cancer patients, offering a noninvasive, accessible method for precision treatment.

Health Canada approves Illuccix for selecting mCRPC patients for PSMA-targeted radionuclide therapy with 177Lu-PSMA-617. Illuccix, initially approved in Canada in 2022 and the US in 2021, aids in staging and re-staging prostate cancer and localizing tumor tissue. The VISION trial data supported FDA approval of 177Lu-PSMA-617 in 2022, showing improved PFS and OS in PSMA-positive mCRPC patients.

Nicole M. Maughan, PhD, receives $100,000 SNMMI Mars Shot Fund award for establishing a centralized dosimetry process with peripheral SPECT/CT image acquisition in radiopharmaceutical therapy, aiming to improve personalized treatment in community practices.

177Lu-PSMA-617 plus docetaxel improved outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) without increased toxicity compared to docetaxel alone, according to the phase 2 UpFrontPSMA study. The addition of lutetium-PSMA to docetaxel significantly improved undetectable PSA levels at 48 weeks and multiple secondary endpoints with no increase in overall toxicity.